Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant RecipientsAndrew H. Karaba, William A. Werbel, Casey Hussey et al.|medRxiv|2022Cited by 21
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipientsAndrew H. Karaba, William A. Werbel, Jake D. Kim et al.|American Journal of Transplantation|2023Cited by 12
Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipientsAlexandra T. Strauss, William A. Werbel, Amy Chang et al.|Liver Transplantation|2022Cited by 7
Letter to the editor: Six‐month antibody kinetics and durability in liver transplant recipients after two doses of SARS‐CoV‐2 mRNA vaccinationAmy Chang, Dorry L. Segev, Alexandra T. Strauss et al.|Hepatology Communications|2022Cited by 3
330.4: SARS-coV-2 Antibody Response to a Third Dose of Homologous mRNA Vaccination in Liver Transplant RecipientsAmy Chang, William A. Werbel, Alexandra T. Strauss et al.|Transplantation|2022Cited by 0